anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a crosslinking agent safe for various organisms of proteins and having effects on formation of an irreversible crosslinking agent, a sustained release agent or a DNA conjugate. SOLUTION: This protein conjugate-forming agent comprises a polyphenol as an active ingredient and is effectively used as a gene conjugate, a cell adhesion inhibitor or an immunological tolerance agent. The principal ingredient of the polyphenol is catechins composed of epigallocatechin gallate, tannin or protocyanidin. The catechins of the polyphenol are useful as a drug delivery formulation of cytokines which are physiologically active proteins by using the catechins of the polyphenol as the conjugate-forming agent for the proteins. Since the catechins of the polyphenol have excellent cell adhesion inhibitory actions, the catechins can be used within a wide range of prophylaxis or treatment such as an immunosuppressive agent, an antiallergic agent, an antimetastasis inhibitor, an eye drop, an ophthalmic perfusion, an antiinflammatory agent, a prophylactic or a therapeutic agent for arteriosclerosis, etc. Furthermore, the catechins can widely be applied even to cord blood, various species of cells and organs for transplantation.
PURPOSE: To study the clinical effectiveness of the topical application of tranexamic acid in hand tendon release.
METHODS: This was a randomized controlled trial conducted after receiving approval from the local ethics committee according to guidelines from the Helsinki Declaration. Eighty patients who underwent hand tendon release operation in our hospital from January 2021 to December 2022 were included and randomly divided into 2 groups. Patients in the tranexamic acid group (40 cases) received intraoperative topical application of 2 g of tranexamic acid after tendon release, while patients in the conventional group (40 cases) did not receive topical application of tranexamic acid during operation. The operation time, perioperative hemoglobin changes, total blood loss, incidence of early postoperative complications, and total active movement (TAM) before surgery and 6 months after surgery were compared between the 2 groups. The continuous variable which follows normal distribution expressed by mean ± SD and used t-test to compare between groups. Meanwhile, categorical variables were used by Chi-square test, and a p < 0.05 indicated that the differences were statistically significant.
RESULTS: Both groups were followed up for 7 - 18 months, with a mean of 10.3 months. Postoperative decrease in hemoglobin was significantly less in the tranexamic acid group than in the conventional group (t = 7.611, p < 0.001). The total blood loss in the tranexamic acid group (74.33 ± 20.50) mL was less than that in the conventional group (83.05 ± 17.73) mL, and the difference was statistically significant (p < 0.05). Both groups showed improvement in thumb/finger flexion and extension range of motion after surgery, and the TAM improved compared with those before surgery, and the difference was statistically significant (p < 0.001). The TAM improved more significantly in the tranexamic acid group (87.68° ± 10.44°) than in the conventional group (80.47° ± 10.93°) at 6 months after surgery, with a statistically significant difference (t = 3.013, p < 0.001). There was no significant difference in operation time and incidence of early postoperative complications between the 2 groups (p = 0.798, 0.499, respectively).
CONCLUSION: The topical application of tranexamic acid during hand tendon release can significantly reduce postoperative bleeding and improve surgical efficacy, which is worth promoting.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
The present invention relates to the application of nano copper powder in the preparation of anti-senility medicine, which has the technical scheme that commercial nano copper powder with the granularity of 0.1 to 1000 nm is adopted as raw material to be prepared into the medicine. A weight ratio between the nano copper powder and a preparation is from 0.002 to 0.04: 1. The nano copper powder has the characteristics of obviously decreasing an MDA content, improving lipid peroxidation damage caused by oxygen free radicals, obviously decreasing an SOD content, intensifying the SOD level of a human body and regulating functional activity expression so as to delay the aging process of the human body and intervene and retard the aging transformation of human body tissue structures. The nano copper powder can be fully regarded as medicine for curing aging resistance, cerebral ischemia, cerebral thrombosis sequelae, etc. In addition, the nano copper powder has outstanding curative effects and can be conveniently and safely taken. The application of nano copper powder in the preparation of anti-senility medicine starts the anti-senility new path of a life science field.
For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
Trial 1:

In a 34-week, open-label trial (Trial 1), insulin-naïve patients with type 2 diabetes mellitus currently treated with 2 oral antidiabetic agents were switched to treatment with metformin and pioglitazone. The mean age of the trial population was 53 years old and mean duration of diabetes was 9.2 years. Forty-six percent were male. Eighty-five percent were White, 12% were Black and 3% were Asian. The mean BMI was approximately 32.4 kg/m2. During an 8-week optimization period metformin and pioglitazone were increased to 2500 mg per day and 30 or 45 mg per day, respectively. After the optimization period, patients were randomized to receive either Insulin Aspart Protamine and Insulin Aspart twice daily added on to the metformin and pioglitazone regimen or continue the current optimized metformin and pioglitazone therapy. Insulin Aspart Protamine and Insulin Aspart was started at a dose of 6 international units twice daily (before breakfast and before supper). Insulin doses were titrated to a pre-meal glucose goal of 80-110 mg/dL. The total daily insulin dose at the end of the study was 56.9 ± 30.5 international units. 

Table 5: Combination Therapy with Metformin and Pioglitazone in Patients with Type 2 Diabetes Mellitus [Mean (SD)] (Trial 1)

     *Adjusted mean per group, treatment difference, and 95% CI were obtained based on an ANCOVA model with treatment, FPG stratum, and secretagogue stratum as fixed factors and baseline HbA1c as the covariate.
     Trial 2:

In a 28-week, open-label trial (Trial 2), insulin-naïve patients with type 2 diabetes with fasting plasma glucose above 140 mg/dL currently treated with metformin ± thiazolidinedione therapy were randomized to receive either Insulin Aspart Protamine and Insulin Aspart twice daily [before breakfast and before supper] or insulin glargine once daily (see Table 6). Insulin Aspart Protamine and Insulin Aspart was started at an average dose of 5-6 international units (0.07 ± 0.03 international units/kg) twice daily (before breakfast and before supper), and bedtime insulin glargine was started at 10-12 international units (0.13 ± 0.03 international units/kg). Insulin doses were titrated weekly by decrements or increments of -2 to +6 units per injection to a pre-meal glucose goal of 80-110 mg/dL. The metformin dose was adjusted to 2,550 mg/day. Approximately one-third of the patients in each group were also treated with pioglitazone (30 mg/day). Insulin secretagogues were discontinued in order to reduce the risk of hypoglycemia. Most patients were White (53%), and the mean initial weight was 90 kg. 

    The mean age of the trial population was 53 years old and mean duration of diabetes was 9.5 years. Fifty three percent were male. Fifty-five percent were White, 15% Black, 27% were Hispanic, 2% were Asian and 2% were Other. The mean BMI was approximately 31.5 kg/m2.

Table 6: Combination Therapy with Metformin ± Pioglitazone and Two Types of Insulin in Patients with Type 2 Diabetes Mellitus [Mean (SD)] (Trial 2)
SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
INTRODUCTION: Treatment of lumbar disc herniation (LDH) using condoliase chemonucleolysis (CC) requires more time than surgery to demonstrate therapeutic effects. This study aimed to identify patients who show significant improvement in leg pain very early after CC and to determine pretreatment factors that can predict a very early therapeutic response.
METHODS: The study included 52 patients who underwent CC for treatment-resistant LDH. Scores for low back and leg pain measured by a numerical rating scale were assessed at four time points (1 day, 1 week, 1 month, and 3 months after CC). Patients who reported subjective pain relief the day after treatment and further exhibited an improved straight leg raising (SLR) angle compared to pretreatment were classified as "very early responders (VER)".
RESULTS: Of the 52 patients, 39 (75%) were VER, and 13 (25%) were non-VER. The VER showed earlier improvement in leg pain. The VER had a significantly higher proportion of positive SLR test patients (p = 0.01) and a significantly smaller pretreatment SLR angle compared to the non-VER (VER vs. non-VER: 40.6 ± 19.0 vs. 63.1 ± 16.9, p < 0.001). There were no significant differences in the level, type, and size of LDH and the disc regression rate between the two groups.
CONCLUSIONS: Patients with a smaller pretreatment SLR angle are more likely to experience very early or early symptomatic relief, with a significant and sustained reduction in leg pain up to 3 months after CC treatment.
Tele-coaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
Myocardial fibrosis (MF) is defined as excessive production and deposition of extra-cellular matrix proteins that result in pathologic myocardial remodeling. Three types of MF have been identified: replacement fibrosis from tissue necrosis, reactive fibrosis from myocardial stress, and infiltrative interstitial fibrosis from progressive deposition of nondegradable material such as amyloid. Although echocardiography, nuclear medicine, and CT play important roles in the assessment of MF, MRI is pivotal in the evaluation of MF, with the late gadolinium enhancement (LGE) technique used as a primary end point. The LGE technique focuses on the pattern and distribution of gadolinium accumulation in the myocardium and assists in the diagnosis and establishment of the cause of both ischemic and nonischemic cardiomyopathy. LGE MRI also aids prognostication and risk stratification. In addition, LGE MRI is used to guide the management of patients considered for ablation for arrhythmias. Parametric mapping techniques, including T1 mapping and extracellular volume measurement, allow detection and quantification of diffuse fibrosis, which may not be detected by LGE MRI. These techniques also allow monitoring of disease progression and therapy response. This review provides an update on the imaging of MF, including prognostication and risk stratification tools, electrophysiologic considerations, and disease monitoring.
BACKGROUND: C-reactive protein (CRP) is a pentameric protein commonly used as a biomarker of inflammation or stress response which can be obtained during routine blood tests. Therefore, we conducted a systematic review and meta-analysis to explore its ability to predict the severity of acute pancreatitis (AP). This meta-analysis was registered in the PROSPERO system (registration number: CRD42022353769).
METHODS: 41 studies with 6156 cases of acute pancreatitis, retrieved from PubMed, Cochrane Library, Springer, and Embase databases, were incorporated. We calculated the pooled estimates for predicting the severity of acute pancreatitis based on CRP levels. We also calculated the combined negative likelihood ratio (NLR), combined positive likelihood ratio (PLR) and combined diagnostic odds ratio (DOR) using a bivariate mixed model. Sensitivity analysis was used to examine the robustness of the results. Factors associated with heterogeneity were identified by meta-regression analysis. A summary operating characteristic (SROC) curve was generated to assess the diagnostic value of CRP in predicting severe acute pancreatitis. Fagan's test was used to calculate likelihood ratios and post-test probabilities, and publication bias was gauged by asymmetry tests.
RESULTS: SROC analysis yielded an AUC of 0.85 (95%CI: 0.81-0.88) with a sensitivity of 0.76 (95%CI: 0.69-0.83) and specificity of 0.79 (95%CI: 0.74-0.83). The combined NLR, PLR and DOR were 0.30 (0.23-0.40), 3.66 (2.94-4.55) and 12.19 (8.05-18.44) respectively. Sensitivity analysis demonstrated the stability of our results after omitting any study. Finally, meta-regression analysis indicated that the description of the reference test, prospective design, blinding method and spectrum of the disease could account for heterogeneity in this meta-analysis.
CONCLUSION: CRP has significant value as a biomarker for assessing AP severity. Besides, other parameters such as patient history, physical signs, and imaging should be considered to determine disease severity.
CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
Cost estimates for brain, lung, cardiac, and kidney complications following complex cardiac surgeries that require a medical assist device to by-pass the heart and lungs (cardiopulmonary bypass, CPB) is estimated to cost $80 million per individual states in the US over a ten-year period. These extra costs represent a significant burden on the healthcare system but could be reduced by understanding how medical assist devices lead to organ injury associated with complex cardiac surgeries. The primary goals of this research are to (1) understand how hemoglobin released into plasma (pfH) from damaged red blood cells that passage through CPB contributes to organ injury. (2) Determine the amount of pfH necessary to cause organ injury. (3) Determine the concentration changes in protective proteins (called haptoglobin, hemopexin and transferrin) that remove pfH and its degradation products from the circulation. (4) Design a computer-based model that will determine the levels of pfH and protective proteins to predict the potential for organ injury. By studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB. The primary goals of this research are to (1) understand how hemoglobin released into plasma (pfH) from damaged red blood cells that passage through CPB contributes to organ injury. (2) Determine the amount of pfH necessary to cause organ injury. (3) Determine the concentration changes in protective proteins (called haptoglobin, hemopexin and transferrin) that remove pfH and its degradation products from the circulation. (4) Design a computer-based model that will determine the levels of pfH and protective proteins to predict the potential for organ injury. By studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
Abstract The method of allowing the selection of a particular cosmetic by packaging the cosmetic in a container having a transparent area permitting an immediate evaluation of the cosmetic relative to the purchaser's skin. Various means may be used to accomplish this.  The container may be provided with a mirror forming one wall, top or bottom.  The mirror has a portion with-out the mirror backing to form a transparent area through which the cosmetic is visible.  The face can then be viewed in the mirror adjacent the cosmetic. The same effect may be used at the sales counter.  A disc is provided with a plurality of pockets sealed with a transparent plastic.  The pockets contain different types, shades, colors, or forms of cosmetic.  A disc mirror is mounted in front of the pockets having one or more unmirrored, transparent openings for viewing one or more pockets.  The pocketed disc is rotatable behind the mirror to allow a view of the person's image in relation to any one of the pocketed cosmetics.  Finally, a sample of cosmetic may be sealed in a small packet of transparent plastic material.  The packet has an opening, the cosmetic surrounding the opening.  The packet can be positioned on the hand or face (before a mirror) to allow a comparison with the skin. The packet may also be made without the opening and provided with an adhesive for pasting to a mirror surface.  The purchaser can compare the face image with the cosmetic in the packet.
A total of 12 studies were performed with epidural administration of Ropivacaine Hydrochloride for cesarean section. Eight of these studies involved 218 patients using the concentration of 5 mg/mL (0.5%) in doses up to 150 mg. Median onset measured at T6 ranged from 11 to 26 minutes. Median duration of sensory block at T6 ranged from 1.7 to 3.2 h, and duration of motor block ranged from 1.4 to 2.9 h. Ropivacaine Hydrochloride provided adequate muscle relaxation for surgery in all cases.

In addition, 4 active controlled studies for cesarean section were performed in 264 patients at a concentration of 7.5 mg/mL (0.75%) in doses up to 187.5 mg. Median onset measured at T6 ranged from 4 to 15 minutes. Seventy-seven to 96% of Ropivacaine Hydrochloride exposed patients reported no pain at delivery. Some patients received other anesthetic, analgesic, or sedative modalities during the course of the operative procedure.
A pre-treatment composition for use in a method of treating a wart or corn comprises a thermal transmission agent for absorption by wart or corn. Preferably the thermal transmission agent is water, further including a surface acting agent e.g. a saponin. The composition may further comprise a tissue-saturating agent e.g. hyaluronic acid, urea, sugars. Also disclosed is a method of treatment comprising applying said thermal transmission agent to a wart/corn; waiting for the composition to penetrate; applying the treatment. The treatment may freeze or heat the wart. The composition may contain an analgesic, anaesthetic or de-sensitising agent. A keratolytic, acid, caustic or vesicating agent may also be applied to the corn/wart. Also disclosed are an apparatus and a kit for use in this method. The kit may contain first and second applicators for the pre-treatment and treatment compositions respectively.
Intramuscular Dosing

The recommended dose is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day. Intramuscular administration of ziprasidone for more than three consecutive days has not been studied.

If long-term therapy is indicated, oral ziprasidone hydrochloride capsules should replace the intramuscular administration as soon as possible.

Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.

Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.

Intramuscular Preparation for Administration

GEODON for Injection (ziprasidone mesylate) should only be administered by intramuscular injection and should not be administered intravenously. Single-dose vials require reconstitution prior to administration.

Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Any unused portion should be discarded. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
SHOULDER SUPPORT-TYPE OF FIREWOOD CARRIER HAVING BUILT-IN          MULTIPLE HANDLES AND A HOOKING COMPONENT            ABSTRACT OF THE DISCLOSURE   A firewood carrying device for carrying logs of wood. The firewood carrying device has a substantially "U"-shaped receptacle body. The receptacle body has a bottom wall, a front wall extending substantially upwardly from the bottom and a back wall also extending substantially upwardly from the bottom wall. A pair of shoulder supporting elements are rigidly fixed to the back wall. Each shoulder supporting element has a substantially "C"-shaped end which extends outwardly from the back wall. The substantially "C"-shaped ends are adapted to be placed over the user's shoulder. A hooking slot extends through the front wall. The firewood carrying device is adapted to be hung to a wall surface. In order to hang the wood carrying device, a hooking pin must first be mounted on the wall surface. The firewood carrying device 10 can then be releasably hooked to the hooking pin by releasably inserting the hooking pin through the hooking slot. The firewood carrier can be loaded and unloaded while it is hung to the wall surface. This method of operation prevents the user from having to bend while holding a relatively heavy loaded firewood carrier. Once the firewood carrier is loaded with logs, it can be lifted off the hook by the user wearing the firewood carrier over his shoulder in an ergonomical fashion. A top handle extending across the upper portion of the firewood carrier between the front wall and the back wall allows the firewood carrier to be handled in a suitcase manner. A pair of side handles extending from the back wall facilitate the ergonomical handling of the firewood carrier.